Clinical trials: Gastroenteropancreatic
Gastroenteropancreatic Neuroendocrine Tumors
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
There is limited evidence regarding the benefit of adding somatostatin analogs to molecular targeted agents for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with poor prognostic factors.
- Trial name
- NCT07165886
- Testing
- Sirolimus for injection (albumin bound), Octreotide long-acting injection, Everolimus
- Where
- China
- Volunteers
- 298 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Gastroenteropancreatic Neuroendocrine Tumors
Incremental Value of Delayed 68Ga-DOTATATE PET/MR in the Detection of Liver Metastases
68-Ga-DOTATATE is a radiotracer targeting somatostatin receptors (SSTR). In this study, we investigated the diagnostic efficacy of delayed ^68^Ga-DOTATATE PET/MR in patients with gastroenteropancreatic neuroendocrine tumors…
- Trial name
- NCT07898904
- Where
- China
- Volunteers
- 46 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Neuroendocrine Tumors, Carcinoma, Small Cell Lung
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Protocol PEN-221-001 is an open-label, multicenter Phase 1/2a study evaluating PEN-221 in patients with SSTR2 expressing advanced gastroenteropancreatic (GEP) or lung or thymus or other neuroendocrine tumors or small cell lung…
- Conditions
- Neuroendocrine Tumors, Carcinoma, Small Cell Lung, Neuroendocrine Carcinoma
- Trial name
- NCT02936323
- Testing
- PEN-221
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 89 people
- Sponsor
- Tarveda Therapeutics
Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [212Pb]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3…
- Conditions
- Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC)
- Trial name
- NCT07278479
- Testing
- [212Pb]Pb-MP0712, [203Pb]Pb-MP0712
- Where
- 8 sites in United States
- Volunteers
- 138 people
- Sponsor
- Molecular Partners AG
Carcinoma, Neuroendocrine
KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.
- Trial name
- NCT02250885
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Gabrail Cancer Center Research
Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors
- Conditions
- Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor
- Trial name
- NCT05636618
- Testing
- [203Pb]VMT-α-NET, [212Pb]VMT-α-NET
- Where
- 20 sites in United States
- Volunteers
- 300 people
- Sponsor
- Perspective Therapeutics
Neuroendocrine Tumors
Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors
The purpose of this study is to verify if adding a locoregional treatment of liver metastasis (with trans-arterial embolization-TAE) to medical treatments of proven efficacy can prolong the progression free survival of patients…
- Trial name
- LOTUS (NCT01755182)
- Testing
- approved pharmacologic therapy, TAE
- Where
- 12 sites in Italy
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute, Naples
GEP-NET
Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET
The current study is an investigator-initiated, single-arm phase 1/2 study that enrolled patients with advanced or recurrent and/or metastatic gastroenteropancreatic poorly differentiated neuroendocrine carcinoma for the…
- Trial name
- NCT05385861
- Testing
- nanoliposomal irinotecan plus carboplatin
- Where
- 6 sites in Taiwan
- Volunteers
- 52 people
- Sponsor
- National Health Research Institutes, Taiwan
Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
The purpose of the current study is to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive…
- Trial name
- NETTER-3 (NCT06784752)
- Testing
- [177Lu]Lu-DOTA-TATE, Octreotide LAR
- Where
- 67 sites in United States, Canada and 10 more
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Gastroenteropancreatic Neuroendocrine Tumor
A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
This study aims to characterize current treatment patterns and clinical outcomes among newly diagnosed GEP-NET patients in the United States using open-source Longitudinal Prescription Claims (LRx) and Patient Centric Medical…
- Trial name
- NCT07635316
- Where
- United States
- Volunteers
- 4,023 people
- Sponsor
- Novartis Pharmaceuticals
Neuroendocrine Tumors
Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice
The main aim of this study is to assess the Progression-Free Survival (PFS) at 12 months of Lanreotide Autogel 120 mg use when administered as part of routine GEP-NET treatment and to follow patient treatment pathways, identify…
- Trial name
- NETways (NCT03895463)
- Where
- 11 sites in Poland
- Sponsor
- Ipsen
Neuroendocrine Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung
Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma
The purpose of this study is to test the efficacy, safety, and tolerability of the combination of chemotherapy treatment, which could be either Cisplatin or carboplatin and etoposide, and the research study drug, Pembrolizumab…
- Conditions
- Neuroendocrine Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, High Grade Neuroendocrine Carcinoma, Any Site
- Trial name
- NCT03901378
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Sponsor
- Ochsner Health System
Neuroendocrine Tumors,Gastroenteropancreatic
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
This is an Open-Label Phase I/II Study of daily cabozantinib plus lanreotide every 4 w eeks to treat advanced G1-2 gastroentero-pancreatic neuroendocrine tumor (GEP-NET) patients who failed to one line or more than one line of…
- Trial name
- NCT05048901
- Testing
- Cabozantinib, Lanreotide
- Where
- 11 sites in Taiwan
- Volunteers
- 49 people
- Sponsor
- National Health Research Institutes, Taiwan
Neuroendocrine Tumors
Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment
The aim of this study is to evaluate the financial toxicity reported by Italian patients affected by GEP-NEN during the first year of treatment after diagnosis and its correlations with patient-reported outcomes (PROs) and…
- Trial name
- FiReNEN (NCT05334290)
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Massimo Falconi
Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the…
- Conditions
- Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
- Trial name
- NCT02595424
- Testing
- Capecitabine, Carboplatin, Cisplatin
- Where
- 673 sites in United States
- Volunteers
- 67 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Neuroendocrine Tumors
Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors
his was a single-center, single-arm phase II study evaluate the efficacy and safety of Lutetium[177Lu] Oxodotreotide Injection in the first-line treatment of unresectable or metastatic, progressive, G2 or G3, somatostatin…
- Trial name
- NCT05894486
- Testing
- Lutetium[177Lu] Oxodotreotide Injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC)
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig…
- Conditions
- Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
- Trial name
- NCT05652686
- Testing
- Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel.
- Where
- 15 sites in United States
- Volunteers
- 203 people
- Sponsor
- Phanes Therapeutics
Gastric Cancer, Pancreatic Cancer
A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors
The purpose of this study is to establish a neuroendocrine tumor registry. A registry is a collection of information. To create this registry, the investigators would like to get information, blood and tumor samples from people…
- Trial name
- NCT00745381
- Testing
- questionnaire, Blood specimens
- Where
- 3 sites in United States
- Volunteers
- 238 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastroenteropancreatic Neuroendocrine Tumor
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
The SAUNA trial is a multi-national, multi-centre, open-label, randomised, controlled, pragmatic clinical trial in patients with advanced, non-functional gastroenteropancreatic (GEP) neuroendocrine tumours (NET) with progressive…
- Trial name
- SAUNA (NCT05701241)
- Testing
- Somatostatin analog
- Where
- 19 sites in Belgium, Netherlands
- Volunteers
- 270 people
- Sponsor
- University Hospital, Antwerp
Gastroenteropancreatic Neuroendocrine Tumors
Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs
This exploratory study aims to evaluate the diagnostic, prognostic and response predictive value of a multi biomarker strategy in patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) originating from the midgut…
- Trial name
- EXPLAIN (NCT02630654)
- Testing
- This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.
- Where
- 25 sites in Denmark, Estonia and 5 more
- Volunteers
- 404 people, healthy volunteers welcome
- Sponsor
- Ipsen